Evidence map›Paper›PMID 35986692›Full record

ArticlePediatric blood & cancer2022

Common bone marrow signature in COVID-19-associated multisystem inflammatory syndrome in children: A first-wave small case series experience.

Maria Antonietta De Ioris, Alessia Scarselli, Claudia Bracaglia, Daniela Perrotta, Stefania Bernardi, Veronica Santilli, Giulia Ceglie, Francesco Fabozzi, Chiara Agrati, Giusi Prencipe and 3 more

Open access · greenAbstract read
In one paragraph

Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Maria Antonietta De IorisDepartment of Haematology/Oncology, Cell and, Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-2113-4505
Alessia ScarselliPediatric Unit, Pediatric Emergency Department (DEA), Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Claudia BracagliaDivision of Rheumatology and Laboratory of ImmunoRheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-9834-9619
Daniela PerrottaDepartment of Anesthesia and Critical Care, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Stefania BernardiPediatric Academic Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Veronica SantilliPediatric Academic Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giulia CeglieDepartment of Haematology/Oncology, Cell and, Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-4127-6914
Francesco FabozziDepartment of Haematology/Oncology, Cell and, Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-3906-4410
Chiara AgratiCellular Immunology Laboratory, IRCCS National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Giusi PrencipeDivision of Rheumatology and Laboratory of ImmunoRheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Rita AlaggioDepartment of Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Angela MastronuzziDepartment of Haematology/Oncology, Cell and, Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Rita De VitoDepartment of Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Bambino Gesù Children's Hospital · ITUniversity of Rome Tor Vergata · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hyper-inflammatory response, also known as multisystem inflammatory syndrome in children (MIS-C), represents a major concern in children with SARS-CoV-2 infection. We report bone marrow features of three patients with MIS-C who were diagnosed during the first wave of the SARS-CoV-2 pandemic. A bone marrow evaluation was performed at onset of the inflammatory condition in order to exclude secondary hemophagocytic lymphohistiocytosis (sHLH). The bone marrows of the patients presented common features: the erythroid and megakaryocytic lineages were prominently affected and hemophagocytosis was moderately increased, differently than observed in sHLH. Megakaryocytopoiesis was increased, representing a peculiar feature of MIS-C differing from sHLH. SARS-CoV-2 RT-PCR and viral panel were studied in bone marrow aspiration samples. MIS-C is a rare complication of SARS-CoV-2 infections in children. An immuno-dysregulation considering both innate and adaptive immunity together with vascular inflammation and endothelial dysfunction play a major role. Our observations, although limited due to the small sample size, suggest that there are unique features in the bone marrow of patients with MIS-C that are likely secondary to immuno-dysregulation, and there are notable differences in bone marrow features compared to those reported in sHLH.

Indexed as

COVID-19Lymphohistiocytosis, HemophagocyticBone MarrowChildHumansPandemicsSARS-CoV-2Systemic Inflammatory Response Syndromebone marrowMIS-CSARS-CoV-2

Identifiers

PMID35986692
PMCPMC9537984
OpenAlexW4292474829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.